📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-01 17:23
169 analysed today
FollowTelegram
169
Today
150,120
All-time analysed
43,024
Positive
6,671
Negative
91,702
Neutral
8,655
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
11 announcements match the current filters (relevance ≥ 5).
National Peroxide Appoints Vinay Jayade as CEO & Whole-Time Director for 5-Year Term
National Peroxide has announced leadership changes following the resignation of Whole-Time Director & CEO Rajiv Arora due to family and personal reasons. Mr. Arora will step down on November 2, 2026, after an orderly transition period. The Board approved the appointment of Vinay Divakar Jayade as CEO and Whole-Time Director for a 5-year term starting November 3, 2026, subject to shareholder approval. Mr. Jayade brings over 34 years of specialty chemicals experience, including prior roles as JV President of Cabot Sanmar and MD of ASK Chemicals India.
Confidence: HIGH
What changedRajiv Arora has resigned as CEO effective November 2, 2026, and Vinay Divakar Jayade has been appointed as his successor for a 5-year term starting November 3, 2026.
Why it mattersA transition in top leadership can influence operational execution, strategy, and business growth, particularly as National Peroxide navigates commodity chemical market cycles.
Appointed term: 5 yearsIncoming CEO experience: over 34 yearsOutgoing CEO relieving date: November 02, 2026New appointment effective date: November 3, 2026
📅 Short termMinimal disruption is anticipated over the next month as both incoming and outgoing CEOs work together during the designated handover period through November 2, 2026.
📈 Long termThe incoming CEO's three-decade chemical industry experience, including M&A and capacity expansion, could support long-term operational and business transformation.
⚠ Risk flags
- Execution disruption during top leadership transition
- Shareholder approval pending for director appointment
Key Highlights
Rajiv Arora resigns as Whole-Time Director & CEO, effective November 2, 2026
Vinay Divakar Jayade appointed as CEO and Whole-Time Director for a term of 5 years starting November 3, 2026
Mr. Jayade will serve as CEO & Whole-Time Director (Designate) during the transition starting October 1, 2026
Incoming CEO brings over 34 years of experience across specialty chemicals and polymer sectors
👀 What to Watch
Track the upcoming shareholder voting for the approval of the new CEO's appointment and monitor upcoming quarterly operational execution under the new leadership.
National Peroxide Appoints Vinay Jayade as CEO & Whole-Time Director for 5-Year Term
National Peroxide has announced leadership changes following the resignation of Whole-Time Director & CEO Rajiv Arora due to family and personal reasons. Mr. Arora will step down on November 2, 2026, after an orderly transition period. The Board approved the appointment of Vinay Divakar Jayade as CEO and Whole-Time Director for a 5-year term starting November 3, 2026, subject to shareholder approval. Mr. Jayade brings over 34 years of specialty chemicals experience, including prior roles as JV President of Cabot Sanmar and MD of ASK Chemicals India.
Confidence: HIGH
What changedRajiv Arora has resigned as CEO effective November 2, 2026, and Vinay Divakar Jayade has been appointed as his successor for a 5-year term starting November 3, 2026.
Why it mattersA transition in top leadership can influence operational execution, strategy, and business growth, particularly as National Peroxide navigates commodity chemical market cycles.
Appointed term: 5 yearsIncoming CEO experience: over 34 yearsOutgoing CEO relieving date: November 02, 2026New appointment effective date: November 3, 2026
📅 Short termMinimal disruption is anticipated over the next month as both incoming and outgoing CEOs work together during the designated handover period through November 2, 2026.
📈 Long termThe incoming CEO's three-decade chemical industry experience, including M&A and capacity expansion, could support long-term operational and business transformation.
⚠ Risk flags
- Execution disruption during top leadership transition
- Shareholder approval pending for director appointment
Key Highlights
Rajiv Arora resigns as Whole-Time Director & CEO, effective November 2, 2026
Vinay Divakar Jayade appointed as CEO and Whole-Time Director for a term of 5 years starting November 3, 2026
Mr. Jayade will serve as CEO & Whole-Time Director (Designate) during the transition starting October 1, 2026
Incoming CEO brings over 34 years of experience across specialty chemicals and polymer sectors
👀 What to Watch
Track the upcoming shareholder voting for the approval of the new CEO's appointment and monitor upcoming quarterly operational execution under the new leadership.
National Peroxide Appoints Vinay Jayade as CEO & Whole-Time Director for 5-Year Term
National Peroxide has announced leadership changes following the resignation of Whole-Time Director & CEO Rajiv Arora due to family and personal reasons. Mr. Arora will step down on November 2, 2026, after an orderly transition period. The Board approved the appointment of Vinay Divakar Jayade as CEO and Whole-Time Director for a 5-year term starting November 3, 2026, subject to shareholder approval. Mr. Jayade brings over 34 years of specialty chemicals experience, including prior roles as JV President of Cabot Sanmar and MD of ASK Chemicals India.
Confidence: HIGH
What changedRajiv Arora has resigned as CEO effective November 2, 2026, and Vinay Divakar Jayade has been appointed as his successor for a 5-year term starting November 3, 2026.
Why it mattersA transition in top leadership can influence operational execution, strategy, and business growth, particularly as National Peroxide navigates commodity chemical market cycles.
Appointed term: 5 yearsIncoming CEO experience: over 34 yearsOutgoing CEO relieving date: November 02, 2026New appointment effective date: November 3, 2026
📅 Short termMinimal disruption is anticipated over the next month as both incoming and outgoing CEOs work together during the designated handover period through November 2, 2026.
📈 Long termThe incoming CEO's three-decade chemical industry experience, including M&A and capacity expansion, could support long-term operational and business transformation.
⚠ Risk flags
- Execution disruption during top leadership transition
- Shareholder approval pending for director appointment
Key Highlights
Rajiv Arora resigns as Whole-Time Director & CEO, effective November 2, 2026
Vinay Divakar Jayade appointed as CEO and Whole-Time Director for a term of 5 years starting November 3, 2026
Mr. Jayade will serve as CEO & Whole-Time Director (Designate) during the transition starting October 1, 2026
Incoming CEO brings over 34 years of experience across specialty chemicals and polymer sectors
👀 What to Watch
Track the upcoming shareholder voting for the approval of the new CEO's appointment and monitor upcoming quarterly operational execution under the new leadership.
₹7 Dividend Confirmed; FY26 Profits Restated Downward Due to ERP Accounting Error
National Peroxide has confirmed a final dividend of ₹7 per share (1.2% yield) for FY26, with the record date set for September 22, 2026. However, the company revealed a significant restatement of its FY26 financial results due to an ERP error that understated natural gas costs, leading to a downward revision of previously reported profits. For Q1 FY27 (June 2026), the company reported revenue of ₹76.40 cr and a net profit of only ₹0.89 cr, a sharp decline from the restated March 2026 quarter profit of ₹5.82 cr. Investors should note the high dividend payout ratio of approximately 43% of restated FY26 PAT despite the internal control lapse and declining quarterly margins.
Confidence: HIGH
What changedThe company corrected a prior accounting error regarding raw material costs and confirmed the ₹7 dividend originally proposed in April 2026.
Why it mattersThe restatement reveals that historical margins were artificially inflated by uncaptured costs; the current Q1 results show the business is struggling with very thin margins (PAT of ₹0.89 cr on ₹76.40 cr revenue).
Dividend per share: ₹7Restated FY26 PAT: ₹9.23 crQ1 FY27 Revenue: ₹76.40 crQ1 FY27 PAT: ₹0.89 crDividend Payout Ratio (Restated): ~43.5%Record Date: September 22, 2026
📅 Short termThe dividend provides a small yield support, but the accounting restatement and poor Q1 performance are likely to weigh on investor sentiment in the coming weeks.
📈 Long termThe company faces structural challenges with low ROCE (4%) and internal control weaknesses; long-term value depends on stabilizing margins in the commodity hydrogen peroxide segment.
⚠ Risk flags
- Internal control weakness (ERP configuration error)
- Significant margin compression in Q1 FY27
- Commodity price sensitivity (Natural Gas)
Key Highlights
Final dividend of ₹7 per equity share (70% of face value) recommended for FY26.
FY26 net profit restated to ₹9.23 cr following discovery of incorrect ERP configuration for natural gas invoices.
Q1 FY27 (June 2026) net profit fell sharply to ₹0.89 cr compared to ₹5.82 cr in the preceding quarter.
Record date for dividend entitlement and AGM participation set for September 22, 2026.
Statutory auditors Kalyaniwalla & Mistry LLP re-appointed for a second 5-year term through FY2031.
👀 What to Watch
Monitor the upcoming AGM on September 29, 2026, for management commentary on internal control remediations and the sharp compression in Q1 FY27 operating margins.
National Peroxide Restates FY26 Profits Due to ERP Error; Confirms ₹7 Dividend
National Peroxide has restated its FY26 and Q3 FY26 financial results following the discovery of an ERP configuration error that understated natural gas costs, leading to a prior overstatement of profits. Despite this correction, the Board maintained its previously recommended final dividend of ₹7 per share (70% of face value). For Q1 FY27 (June 2026), the company reported a revenue of ₹76.40 Cr and a net profit of ₹0.89 Cr, with an EPS of ₹1.55. The record date for the dividend and the 6th Annual General Meeting is set for September 22, 2026.
Confidence: HIGH
What changedThe company corrected a material accounting error regarding natural gas costs and released its Q1 FY27 results while setting the timeline for its annual dividend payout.
Why it mattersProfit restatements due to internal system errors can impact investor confidence in financial reporting; however, the maintenance of the dividend suggests the cash flow position remains stable enough to support the payout.
Dividend per share: ₹7Dividend Yield (at ₹575.2): 1.22%Q1 FY27 Revenue: ₹76.40 CrQ1 FY27 Net Profit: ₹0.89 CrRecord Date: September 22, 2026
📅 Short termThe stock may face pressure due to the profit restatement news, though the confirmed dividend provides a minor support level.
📈 Long termThe company needs to address its low ROCE (4.0%) and ensure the robustness of its ERP systems to regain full investor trust in its financial disclosures.
⚠ Risk flags
- Accounting error leading to profit restatement
- Low ROCE of 4.0%
- Commodity chemical price sensitivity (Natural Gas)
Key Highlights
Restatement of FY26 results due to incorrect ERP configuration for natural gas invoices, which understated raw material costs.
Final dividend of ₹7 per share confirmed for FY26, representing a 70% payout on the ₹10 face value.
Q1 FY27 revenue reported at ₹76.40 Cr, approximately 26% of the TTM revenue of ₹290 Cr.
Q1 FY27 net profit stood at ₹0.89 Cr with an EPS of ₹1.55, matching the previous year's June quarter performance.
Record date for dividend entitlement and AGM participation fixed as September 22, 2026.
👀 What to Watch
Investors should monitor the revised FY26 audit report for the exact magnitude of the profit overstatement and watch for improvements in internal financial controls to prevent future ERP-related accounting errors.
National Peroxide Restates FY26 Profits Due to ERP Error; Maintains Rs 7 Dividend
National Peroxide has restated its FY26 financial results following the discovery of an ERP configuration error that understated natural gas costs and overstated profits. Despite this correction, the Board has maintained its recommended final dividend of Rs 7 per share (70% of face value). For the first quarter of FY27 (ended June 30, 2026), the company reported a Profit After Tax of Rs 5.82 crore. The 6th Annual General Meeting is scheduled for September 29, 2026, with a record date of September 22, 2026.
Confidence: HIGH
What changedThe company corrected a material accounting error regarding raw material costs and formalized its AGM and dividend payment schedule.
Why it mattersThe restatement indicates a lapse in internal financial controls, though the maintenance of the dividend and a profitable Q1 FY27 provide some reassurance to shareholders.
Dividend per share: Rs 7Q1 FY27 PAT: Rs 5.82 CrRestated FY26 PAT: Rs 9.23 CrDividend Yield (approx): 1.2%Record Date: September 22, 2026
📅 Short termThe restatement of past profits may lead to short-term price volatility as investors digest the impact on historical margins.
📈 Long termLimited structural impact provided the ERP error is a one-off event and operational profitability remains stable.
⚠ Risk flags
- Internal control weakness (ERP configuration error)
- Raw material (natural gas) price sensitivity
Key Highlights
Restatement of FY26 and Q3 FY26 results due to incorrect natural gas invoice processing in the ERP system
Recommended final dividend of Rs 7 per share (70%) for FY26 remains unchanged
Reported Q1 FY27 (June 2026) Profit After Tax of Rs 5.82 crore
Record date for dividend and AGM entitlement set for September 22, 2026
Statutory auditors Kalyaniwalla & Mistry LLP reappointed for a second 5-year term until FY31
👀 What to Watch
Monitor the company's upcoming annual report for details on internal control improvements to prevent further ERP-related accounting errors.
National Peroxide Restates FY26 Profit Downward to ₹9.23 Cr; Maintains ₹7 Dividend
National Peroxide has restated its FY26 and Q3 FY26 financial results due to an ERP configuration error that understated natural gas raw material costs. The revised FY26 Profit After Tax (PAT) is now ₹9.23 Cr, a downward revision from previously reported figures. Despite the accounting error, the Board maintained its recommended final dividend of ₹7 per share (70% of face value). For Q1 FY27 (ended June 2026), the company reported a PAT of ₹5.82 Cr, showing a recovery compared to the restated Q4 FY26 PAT of ₹0.89 Cr.
Confidence: HIGH
What changedThe company corrected a material accounting error related to natural gas costs and reported its Q1 FY27 earnings alongside a confirmed dividend timeline.
Why it mattersA profit restatement indicates a lapse in internal controls, which is a governance concern, although the auditor issued an unmodified opinion. The dividend payout remains significant at approximately 43% of the revised annual profit.
Revised FY26 PAT: ₹9.23 CrQ1 FY27 PAT: ₹5.82 CrDividend per Share: ₹7Dividend Yield: 1.21%Record Date: September 22, 2026
📅 Short termThe stock may experience volatility as the market digests the downward profit restatement and the internal control lapse in the ERP system.
📈 Long termThe company's ability to maintain margins in the commodity chemicals space while managing raw material costs (natural gas) will be the primary driver for long-term valuation.
⚠ Risk flags
- Internal control weakness (ERP configuration error)
- Commodity price risk (Natural Gas)
- Downward profit restatement
Key Highlights
Restatement of FY26 results due to incorrect ERP configuration for natural gas invoices, leading to previously overstated profits.
Revised FY26 Profit After Tax stands at ₹9.23 Cr, while Q1 FY27 PAT is reported at ₹5.82 Cr.
Final dividend of ₹7 per share recommended, representing a ~1.2% yield on the current price of ₹575.2.
Record date for the dividend and 6th Annual General Meeting set for September 22, 2026.
Reappointment of M/s. Kalyaniwalla & Mistry LLP as Statutory Auditors for a second 5-year term until FY31.
👀 What to Watch
Investors should monitor management's commentary during the AGM on September 29, 2026, regarding the strengthening of internal financial controls and ERP systems to prevent future restatements.
Q1 Profit Rises to ₹5.82 Cr; FY26 Results Restated Downward due to ERP Accounting Error
National Peroxide reported a significant recovery in Q1 FY27, with net profit jumping to ₹5.82 Cr from ₹0.89 Cr in the year-ago period. Revenue grew 13.5% YoY to ₹76.40 Cr. However, the company has retrospectively restated its FY26 results downward after discovering an ERP configuration error that understated natural gas costs. The revised FY26 PAT is now ₹9.23 Cr, down from the previously reported ~₹11 Cr. The board confirmed a final dividend of ₹7 per share with a record date of September 22, 2026.
Confidence: HIGH
What changedThe company corrected a historical accounting error regarding raw material costs while simultaneously reporting a strong operational turnaround in the current quarter.
Why it mattersThe restatement reveals that historical profitability was lower than initially reported due to gas cost underestimation; however, the Q1 results suggest a genuine operational recovery in the hydrogen peroxide business.
Q1 FY27 Net Profit: ₹5.82 CrQ1 FY27 Revenue: ₹76.40 CrRevised FY26 EPS: ₹16.06Dividend per share: ₹7.00Record Date: Sept 22, 2026
📅 Short termThe stock may see mixed reactions: positive for the strong Q1 earnings growth but cautious regarding the accounting restatement and internal control issues.
📈 Long termThe structural recovery in margins is positive, but the company needs to demonstrate consistent accounting integrity and manage volatile input (natural gas) costs effectively.
⚠ Risk flags
- Accounting error in ERP system
- Natural gas price volatility
- Small-cap liquidity risk
Key Highlights
Q1 FY27 net profit increased to ₹5.82 Cr, a 554% jump from ₹0.89 Cr in Q1 FY26.
Revenue for the June 2026 quarter rose to ₹76.40 Cr compared to ₹67.32 Cr in the previous year's corresponding quarter.
FY26 financial results restated due to incorrect ERP configuration for natural gas invoices, which previously overstated profits.
Final dividend of ₹7 per share (70%) confirmed for FY26, representing a yield of ~1.2% at current prices.
Statutory auditors Kalyaniwalla & Mistry LLP reappointed for a second 5-year term until FY2031.
👀 What to Watch
Investors should monitor the sustainability of the improved Q1 margins and verify if the internal control weaknesses related to the ERP system have been fully remediated.
National Peroxide Revises FY26 PAT Downward to ₹9.23 Cr Due to ERP Accounting Error
National Peroxide has restated its FY26 financial results following the discovery of an ERP configuration error that understated natural gas costs. The revised FY26 Profit After Tax (PAT) stands at ₹9.23 Cr, a reduction from the previously reported figures. For Q1 FY27, the company reported a PAT of ₹5.82 Cr on revenue of ₹84.47 Cr, showing a strong start to the new fiscal year. The board maintained its recommended final dividend of ₹7 per share (70%) despite the restatement.
Confidence: HIGH
What changedThe company retrospectively restated its FY26 and Q3 FY26 results to correct an understatement of raw material (natural gas) costs caused by an ERP system error.
Why it mattersThe restatement reveals a weakness in internal accounting controls but provides a more accurate baseline for margins; the Q1 FY27 results indicate that current profitability is significantly higher than the FY26 average.
Revised FY26 PAT: ₹9.23 CrQ1 FY27 PAT: ₹5.82 CrQ1 FY27 Revenue: ₹84.47 CrDividend per share: ₹7.00Record Date: September 22, 2026
📅 Short termThe stock may face pressure due to the profit restatement and governance concerns regarding ERP errors, though the dividend and Q1 growth may provide support.
📈 Long termLimited structural change; the company remains a single-segment player in Hydrogen Peroxide, and long-term value depends on managing volatile input costs like natural gas.
⚠ Risk flags
- Internal financial control weakness (ERP error)
- Natural gas price volatility
- Single product concentration
Key Highlights
Revised FY26 PAT stands at ₹9.23 Cr following a retrospective restatement due to ERP invoice processing errors.
Q1 FY27 PAT reported at ₹5.82 Cr, which is approximately 63% of the total revised PAT for the entire previous year.
Q1 FY27 Revenue from operations reached ₹84.47 Cr, representing ~29% of TTM revenue.
Final dividend of ₹7 per share (70%) confirmed with a Record Date of September 22, 2026.
Statutory auditors re-appointed for a second 5-year term until FY31, subject to AGM approval.
👀 What to Watch
Investors should monitor the company's internal financial control disclosures in the upcoming Annual Report to ensure the ERP configuration issues are fully resolved. The strong Q1 FY27 performance provides some cushion against the negative sentiment of the restatement.
National Peroxide revises FY26 PAT to ₹9.23 Cr; reports Q1 FY27 PAT of ₹6.61 Cr
National Peroxide has restated its FY26 and Q3 FY26 financial results due to an ERP configuration error that understated natural gas costs, leading to a prior overstatement of profits. The revised FY26 PAT now stands at ₹9.23 Cr. For the current quarter (Q1 FY27), the company reported a PAT of ₹6.61 Cr on a total income of ₹84.47 Cr. The board maintained its ₹7 per share dividend recommendation and reappointed its statutory auditors for a five-year term.
Confidence: HIGH
What changedThe company retrospectively restated its FY26 financials to correct an accounting error in raw material costs and released its Q1 FY27 results.
Why it mattersThe restatement indicates a lapse in internal controls related to ERP systems, which impacted reported profitability. However, the Q1 FY27 results suggest the business remains profitable despite these adjustments.
Revised FY26 PAT: ₹9.23 CrQ1 FY27 PAT: ₹6.61 CrDividend per share: ₹7Q1 FY27 Revenue: ₹84.47 CrRecord Date: September 22, 2026
📅 Short termThe stock may face pressure due to the accounting restatement and the 'Emphasis of Matter' by auditors, though the sequential profit growth in Q1 FY27 provides some fundamental support.
📈 Long termStructural growth depends on the company's ability to manage volatile natural gas costs and maintain its market position in the Hydrogen Peroxide segment.
⚠ Risk flags
- Internal control weakness (ERP accounting error)
- Raw material price sensitivity (Natural Gas)
- Single product concentration (Hydrogen Peroxide)
Key Highlights
Revised FY26 PAT to ₹9.23 Cr from previously reported figures due to natural gas invoice processing errors in the ERP system
Reported Q1 FY27 PAT of ₹6.61 Cr, showing significant recovery compared to the revised Q4 FY26 PAT of ₹0.89 Cr
Maintained final dividend of ₹7 per equity share (70%) for FY26, with a record date set for September 22, 2026
Reappointed M/s. Kalyaniwalla & Mistry LLP as Statutory Auditors for a second 5-year term until FY31
Total income for Q1 FY27 stood at ₹84.47 Cr with an EPS of ₹11.50 for the quarter
👀 What to Watch
Investors should monitor the company's disclosure regarding internal financial control improvements to address the ERP configuration issues. The operational recovery in Q1 FY27 is positive, but the sensitivity to natural gas pricing remains a key variable for this single-segment business.
National Peroxide Restates FY26 Profits Due to ERP Error; Maintains ₹7 Dividend
National Peroxide has retrospectively restated its FY26 and Q3 FY26 financial results following the discovery of an ERP configuration error that understated natural gas costs, leading to a prior overstatement of profits. For the new quarter ended June 30, 2026, the company reported a net profit of ₹0.89 Cr on revenue of ₹84.47 Cr. Despite the accounting correction, the board maintained its recommended final dividend of ₹7 per share (70%). The statutory auditor has been reappointed for a second 5-year term, though the revised audit report includes an 'Emphasis of Matter' regarding the restatement.
Confidence: HIGH
What changedThe company corrected its historical financial statements for FY26 due to an accounting error and released its Q1 FY27 results.
Why it mattersThe restatement highlights a weakness in internal controls regarding raw material cost accounting, which is critical for a commodity chemical business with thin margins.
Dividend per share: ₹7Q1 FY27 Revenue: ₹84.47 CrQ1 FY27 Net Profit: ₹0.89 CrRecord Date: September 22, 2026Dividend Payout vs TTM PAT: ~36%
📅 Short termThe stock may face negative sentiment in the short term due to the admission of profit overstatement and accounting errors.
📈 Long termLimited structural impact if the ERP issue is isolated, but the company needs to demonstrate improved reporting rigor and margin stability.
⚠ Risk flags
- Internal control weakness (ERP configuration error)
- Raw material cost sensitivity (Natural Gas)
- Profit overstatement in prior periods
Key Highlights
Restatement of FY26 and Q3 FY26 results due to incorrect ERP configuration for natural gas invoices.
Maintained final dividend of ₹7 per equity share (70%) for the financial year ended March 31, 2026.
Reported Q1 FY27 net profit of ₹0.89 Cr, a significant drop from the restated Q4 FY26 profit of ₹5.82 Cr.
Record date for the final dividend and 6th Annual General Meeting set for September 22, 2026.
Statutory auditors Kalyaniwalla & Mistry LLP reappointed for a 5-year term until the 11th AGM in 2031.
👀 What to Watch
Investors should monitor the upcoming Annual Report for details on how internal financial controls are being strengthened to prevent future ERP-related accounting errors.
